On Nov 14, major Wall Street analysts update their ratings for $Sangamo Therapeutics (SGMO.US)$, with price targets ranging from $3 to $10.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $9.
Wells Fargo analyst Yanan Zhu maintains with a hold rating, and adjusts the target price from $1 to $3.
TD Cowen analyst Ritu Baral maintains with a buy rating.
H.C. Wainwright analyst Patrick Trucchio maintains with a buy rating, and maintains the target price at $10.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's third-quarter report, there's an acknowledgment of the alignment with the FDA for an accelerated approval pathway. The discussion during the Q3 call primarily centered on the advancement of the Fabry program and the ongoing late-stage partnership talks. There is anticipation of favorable data by the third quarter of 2025 and potential FDA approval by 2026, with the expectation of a partnership deal being announced shortly.
The firm considers the establishment of a partnership regarding the Fabry program and the complete results from the pivotal study as crucial catalysts. It is believed that the potential rise in the stock's value will stem from the proof of concept of the company's proprietary ZFP transcription factor neurology programs.
Here are the latest investment ratings and price targets for $Sangamo Therapeutics (SGMO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月14日，多家华尔街大行更新了$Sangamo Therapeutics (SGMO.US)$的评级，目标价介于3美元至10美元。
巴克莱银行分析师Gena Wang维持买入评级，维持目标价9美元。
富国集团分析师Yanan Zhu维持持有评级，并将目标价从1美元上调至3美元。
TD Cowen分析师Ritu Baral维持买入评级。
H.C. Wainwright分析师Patrick Trucchio维持买入评级，维持目标价10美元。
此外，综合报道，$Sangamo Therapeutics (SGMO.US)$近期主要分析师观点如下：
在Sangamo发布第三季度报告后, 公司对与FDA就加速批准途径的对齐表示认可。在Q3电话会议期间, 讨论主要集中在Fabry项目的推进以及正在进行的后期合作谈判。预计到2025年第三季度将有有利数据出现, 并有望在2026年获得FDA批准, 预计合作协议将很快宣布。
该公司认为, 就Fabry项目的合作伙伴关系的建立以及关键研究的完整结果是至关重要的催化剂。据信, 股票价值的潜在上涨将源自公司专有的ZFP转录因子神经学项目的概念证明。
以下为今日4位分析师对$Sangamo Therapeutics (SGMO.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
